Cellular immunity to viral and fungal antigens after stem cell transplantation

Current Opinion in Hematology

Volumn 9, Issue 6, 2002, Pages 485-489

  Einsele, Hermann ^a   Hebart, Holger ^a  

^a Innere Medizin II Onkologie Haematologie Immunologie Rheumatologie und Pulmologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIGEN; VIRUS ANTIGEN;

ANTIBIOTIC THERAPY; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; STEROID THERAPY; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS REACTIVATION; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; OPPORTUNISTIC INFECTION;

ANTIGENS, FUNGAL; ANTIGENS, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOTHERAPY; OPPORTUNISTIC INFECTIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036838312     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200211000-00003     Document Type: Review

References (36)

1. Sester M, Sester U, Gartner B, et al.: Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 2002, 76:3748-55
2. Chakraverty R, Robinson S, Peggs K, et al.: Excessive T-cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001, 28:827-834.
3. Hebart H, Brugger W, Grigoleit U, et al.: Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001, 97:2183-2185.
4. Cwynarski K, Ainsworth J, Cobbold M, et al.: Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97:1232-1240.
5. Benz C, Utermohlen O, Wulf A, et al.: Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients. Gastroenterology 2002, 122:1201-15.
6. Aubert G, Hassan-Walker AF, Madrigal JA, et al.: Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001, 184:955-63.
7. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001, 98:1358-1364.
8. Hebart H, Daginik S, Stevanovic S, et al.: Sensitive detection of HCMV peptide-specific CTL-responses by IFN-gamma EL ISPOT and flow cytometry in healthy individuals and patients following allogeneic stem cell transplantation. Blood 2002, 99:3830-3837.
9. Schäfer H, Berger C, Aepinus C, et al.: Molecular pathogenesis of Epstein-Barr virus-associated posttransplant lymphomas: new insights through latent membrane protein fingerprinting. Transplantation 2001, 72:492-496.
10. Nolte A, Buhmann R, Emmerich B, et al.: Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with Non-Hodgkin's lymphoma British Journal of Hematology 2000, 108:415-423.
11. Gustafsson A, Levitsky V, Zou JZ, et al.: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95:807-814.
12. Sester M., Sester U., Salvador SA, et al.: Age-related decrease in adenovirus-specific T-cell responses. J Infect Dis 2002, 185:1379-1387.
13. Grazziutti M, Przepiorka D, Rex JH, et al.: Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant 2001, 27:647-652.
14. Bozza S, Gaziano R, Spreca A, et al.: Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002, 168:1362-1371.
15. Bacci A, Montagnoli C, Perruccio K, et al.: Dendritic cells pulsed with fungal RNA induce protective immunity to candida albicans in hematopoietic transplantation. J Immunol 2002, 168:2904-2913.
16. H2 cytokine antagonists. Blood 2001, 97:1483-1490.
17. Garcia-Diaz JB, Palau L, Pankey GA: Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis 2001, 32:166-170.
18. Kleihauer A, Grigoleit U, Hebart H, et al.: Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol 2001, 113:231-239.
19. Koehne G, Smith KM, Ferguson TL, et al.: Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002, 99:1730-40.
20. Sauce D, Bodinier M, Garin M, et al.: Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002, 99:1165-73.
21. Peggs K, Verfuerths S, Mackinnon S: Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001, 97:994-1000.
22. + T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 2002, 99:213-223.
23. Szmania S, Galloway A, Bruorton M, et al.: Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001, 98:505-12.
24. + T cells. J Immunol 2001, 15:166:5250-5257.
25. Keever-Taylor CA, Margolis D, Konings S, et al.: Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant 2001, 7:247-56.
26. Hamel Y, Blake N, Gabrielsson S, et al.: Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr Virus EBNA3C Protein: A novel approach for immunotherapy. Hum Gene Ther 2002, 13:855-66.
27. Lucas KG, Sun Q, Burton RL, et al.: A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T-cell-depleted stem cell transplants. Hum Gene Ther 2000, 11:1453-1463.
28. + T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 2001, 75:7840-7847.
29. + T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J Virol 2002, 76:142-50.
30. + cytotoxic T cells from Virus naive Individuals. J Immunol 2002, 168:909-918.
31. Berencsi K, Gyulai Z, Gonczol E, et al.: A canarypox vector expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T-cell responses in human CMV-seronegative subjects. J Infect Dis 2001, 183:1171-1179.
32. Gottschalk S, Ng CY, Perez M, et al.: An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97:835-843.
33. Rossig G, Bollard CM, Nuchtern JG, et al.: Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-2016.
34. Einsele H, Roosnek E, Rufer N, et al.: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-22.
35. Peggs KS, Mackinnon S: Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation. Br J Haematol 2001, 115:1032-1033.
36. Keenan RD, Ainsworth J, Khan N, et al.: Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide teramers. Br J Haematol 2002, 115:428-434.